101 
Market Cap
As of July 16, 2010: $495,024,000.00
Stock Chart
Sigma Pharmaceuticals - 30 Day Poll
Recent BLOGS About Sigma Pharma Add New
There are no blogs to display.
Latest Company News
|
Sigma Pharmaceuticals appoints CFO
Business Spectator - Jul 28, 2010 By a staff reporter Troubled pharmaceuticals group Sigma Pharmaceuticals has announced the appointment of Jeff Sells as its new chief financial officer. Mr Sells, who has a background in corporate ...
|
|
Sigma Pharmaceutical Limited Gets Three Bids Each For Two Drug Arms-Reuters
Reuters Key Development - Jul 18, 2010 |
|
DEALS TV: McGauchie's new headache
Business Spectator - Jul 16, 2010 Glycophosphate maker's new chairman rides into a storm, while AIR NZ play downs Virgin Blue stake talk. Elsewhere, the battle for Playboy heats up. Do you have a rumour, tip or story idea for ...
|
|
Market Wrap: Aus stocks close lower
Finance News Network - Jul 15, 2010 The Australian share market closed lower today as worries about a slowdown in the US economy lingered and data showed an easing in China's gross domestic product growth. Data released today showed ...
|
|
Midday: Aus shares lower
Finance News Network - Jul 15, 2010 Australian shares are lower at midday, declines in the miners on softer commodity prices, dragging on the market. The S&P/ASX200 index is down 25 points at 4,437 and on the futures market, the ...
|
|
Sigma cuts profit guidance
Business Spectator - Jul 14, 2010 By a staff reporter, with Reuters/AAP Sigma Pharmaceuticals Ltd has cut its full-year profit forecast by about 31 per cent as it attempts to persuade South Africa's Aspen Pharmacare to improve its ...
|
|
Sigma Pharmaceutical Limited Lowers FY 2011 Profit Guidance-Reuters
Reuters Key Development - Jul 14, 2010 |
Website
Videos related to Sigma Pharma
Company Profile
Sigma Pharmaceuticals Limited is engaged in the manufacturing, marketing and wholesale distribution of pharmaceutical products through the pharmacy and grocery channels and the provision of services to retail pharmacists.
The Company operates in three business segments: pharmaceuticals, healthcare and corporate. The pharmaceuticals segment includes contract manufacture for Australian and overseas pharmaceutical companies, and the manufacturing, selling and marketing of Sigma, Arrow, Herron and other pharmaceutical products.
The healthcare segment includes wholesale and distribution to pharmacy of prescription and over the counter products, management of banner groups and the development and provision of private label products.
The corporate segment includes corporate head office costs and all items associated with the New Zealand operations. In 2008 the Company completed the acquisition of Orphan Holdings Pty Limited.
The Company operates in three business segments: pharmaceuticals, healthcare and corporate. The pharmaceuticals segment includes contract manufacture for Australian and overseas pharmaceutical companies, and the manufacturing, selling and marketing of Sigma, Arrow, Herron and other pharmaceutical products.
The healthcare segment includes wholesale and distribution to pharmacy of prescription and over the counter products, management of banner groups and the development and provision of private label products.
The corporate segment includes corporate head office costs and all items associated with the New Zealand operations. In 2008 the Company completed the acquisition of Orphan Holdings Pty Limited.
Terms & Rules
As per ASIC Regulatory Guide 162: All investment tips and comments appearing on this website (Poll results, BLOGS & discussion forums) are submitted by the general public who are not licensed financial advisors. None of the information on this website is financial or investment advice, you should seek independent financial or investment advice by a licensed financial or investment advisor before entering into any position of financial risk. Before using this website, you must agree to the BioInvesting.com.au Terms Of Use